Free Trial
OTCMKTS:ALPMY

Astellas Pharma (ALPMY) Stock Price, News & Analysis

Astellas Pharma logo
$11.24 -0.32 (-2.77%)
As of 09/19/2025 03:59 PM Eastern

About Astellas Pharma Stock (OTCMKTS:ALPMY)

Advanced

Key Stats

Today's Range
$10.78
$11.55
50-Day Range
$9.66
$11.71
52-Week Range
$8.37
$12.55
Volume
109,153 shs
Average Volume
81,441 shs
Market Capitalization
N/A
P/E Ratio
37.47
Dividend Yield
3.11%
Price Target
N/A
Consensus Rating
Buy

Company Overview

Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALPMY Stock News Headlines

Zacks Research Upgrades Astellas Pharma (OTCMKTS:ALPMY) to "Strong-Buy"
Strange crypto pattern discovered by 40-person research team
Something unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary people pull consistent profits from crypto — not through luck or timing, but through a systematic approach with a documented 93% win rate.tc pixel
See More Headlines

ALPMY Stock Analysis - Frequently Asked Questions

Astellas Pharma's stock was trading at $9.66 on January 1st, 2025. Since then, ALPMY shares have increased by 16.4% and is now trading at $11.24.

Astellas Pharma Inc. (OTCMKTS:ALPMY) released its quarterly earnings results on Wednesday, July, 30th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.26. The business had revenue of $3.41 billion for the quarter, compared to the consensus estimate of $3.20 billion. Astellas Pharma had a trailing twelve-month return on equity of 19.67% and a net margin of 4.34%.

Shares of Astellas Pharma split on the morning of Wednesday, April 2nd 2014.The 5-4 split was announced on Friday, March 14th 2014. The newly issued shares were issued to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

Astellas Pharma subsidiaries include Iota Biosciences, Nanna Therapeutics, Xyphos, Audentes Therapeutics, Potenza Therapeutics, Quethera, Universal Cells Inc., and more.

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
7/30/2025
Today
9/20/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
N/A
Current Symbol
OTCMKTS:ALPMY
CIK
1446390
Fax
N/A
Employees
14,754
Year Founded
1923

Profitability

EPS (Trailing Twelve Months)
$0.30
Trailing P/E Ratio
37.47
Forward P/E Ratio
26.76
P/E Growth
N/A
Net Income
$334.93 million
Net Margins
4.34%
Pretax Margin
1.63%
Return on Equity
19.67%
Return on Assets
8.71%

Debt

Debt-to-Equity Ratio
0.38
Current Ratio
1.17
Quick Ratio
0.89

Sales & Book Value

Annual Sales
$12.56 billion
Price / Sales
N/A
Cash Flow
$1.80 per share
Price / Cash Flow
6.25
Book Value
$5.52 per share
Price / Book
2.04

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.27

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (OTCMKTS:ALPMY) was last updated on 9/21/2025 by MarketBeat.com Staff
From Our Partners